title: [Is the use of ribavirin aerosols in respiratory syncytial virus infections justified? Clinical and economic evaluation].
abstract: The controversy about the use of ribavirin aerosol for children at risk (cardiopathy, pneumopathy, premature and immunodeficient patients), in case of respiratory syncytial virus (RSV) infection, led us to stop its prescription in 1993 and study prospectively the patients admitted during the following winters.
  
  
  METHODS
  Criterias of inclusion for this study were those of the Committee on Infectious Diseases of the American Academy of Pediatrics concerning the use of ribavirin aerosol. Two cohorts of patients were studied: the first group included treated patients (ribavirin group: n = 22, ribavirin and support treatment: salbutamol aerosols, respiratory physiotherapy and oxygen-therapy; winters 1989-1990 to 1992-1993); the second group included patients with support treatment only (control group: n = 22; winters 1993-1994 and 1994-1995).
  
  
  RESULTS
  The clinical gravity score at admission (4.55 vs 5.23, P = 0.46) and the risk factor scores (3.05 vs 3.27, P = 0.69) of the two groups were identical. Results showed that the children of the ribavirin group stayed much longer in hospital (14.2 vs 8.2 days, P = 0.002) and in the intensive care unit (7.2 vs 0.2 days, P < 0.001) than those of the control group. More support treatment was necessary for the ribavirin group as regard respiratory physiotherapy (3.8 vs 2.7 sessions a day, P = 0.026), the duration of oxygen-therapy (7.3 vs 3.7 days, P = 0.030) and the number of children requiring respiratory assistance (4 vs 0 children, P = 0.116). Administration of ribavirin aerosols (480 US$ a dose) and the way in which such treatment was carried out meant high daily costs for the ribavirin group (1,076 vs 604 US$, P < 0.001). As hospitalization was longer for children treated with ribavirin, the global cost was therefore much higher (15,552 vs 5,156 US$, P < 0.001).
  
  
  CONCLUSIONS
  The antiviral effect of ribavirin is undeniable. However ribavirin is known to be the cause of severe bronchospasms (two cases in our study) and can also cause moderate and long term bronchospasms, aggravating therefore the clinical evolution of the disease. Our experience shows that administration of ribavirin aerosols in case of RSV infection of inferior respiratory airways seems not to be justified.
authors.affiliation: Service de pédiatrie, centre hospitalier universitaire vaudois, Lausanne, Suisse.
authors.forename: F
authors.initials: F
authors.lastname: Ventura
authors.forename: J J
authors.initials: JJ
authors.lastname: Cheseaux
authors.forename: J
authors.initials: J
authors.lastname: Cotting
authors.forename: J P
authors.initials: JP
authors.lastname: Guignard
mesh_terms: D000336:Aerosols; D000420:Albuterol / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D015331:Cohort Studies; D003365:Costs and Cost Analysis; D005260:Female; D005602:France; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control; D012138:Respiratory Therapy; D012254:Ribavirin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D012307:Risk Factors
chemical_list: D000336:Aerosols; D000998:Antiviral Agents; D012254:Ribavirin; D000420:Albuterol